Induction of MDR1 gene expression by anthracycline analogues in a human drug resistant leukaemia cell line

XF Hu1, A Slater1, D Rischin1, P Kantharidis1, JD Parkin2 and J Zalcberg1

1Trescowthick Laboratory, Peter MacCallum Cancer Institute, Melbourne, Australia; 2Division of Pathology, Austin and Repatriation Medical Centre, Melbourne, Australia

Summary The effects of 4-demethoxydaunorubicin (idarubicin, IDA) and MX2, a new morpholino-anthracycline, on up-regulation of the MDR1 gene in the low-level multidrug resistant (MDR) cell line CEM/A7R were compared at similar concentrations (IC10, IC50 and IC90) over a short time exposure (4 and 24 h). The chemosensitivity of each drug was determined by a 3-day cell growth inhibition assay. Compared with epirubicin (EPI), IDA and MX2 were 17- and eightfold more effective in the CEM/A7R line respectively. No cross-resistance to 5-FU was seen in the CEM/A7R line. Verapamil (5 μM) and PSC 833 (1 μM), which dramatically reversed resistance to EPI in the CEM/A7R line, had no sensitizing effect on the resistance of this line to MX2, but slightly decreased resistance to IDA. The sensitivity to 5-FU was unchanged by these modulators. The induction of MDR1 mRNA expression by IDA, MX2 and 5-FU was analysed by Northern blotting and semiquantitatively assessed by scanning Northern blots on a phosphorimager. The relative level of MDR1 expression was expressed as a ratio of MDR1 mRNA to the internal RNA control glyceraldehyde-3-phosphate dehydrogenase (GAPDH). IDA, MX2 and 5-FU differentially up-regulated MDR1 expression paralleled the increase in MDR1 mRNA levels. For the three anthracyclines, the increase in MDR1 expression was stable in cells grown in the absence of drug for more than 3 weeks after drug treatment. The induction of MDR1 expression by 5-FU was transient, associated with a rapid decrease in the increased Pgp levels which returned to baseline 72 h after the removal of 5-FU. This study demonstrates that MDR1 expression can be induced by analogues of anthracyclies not pumped by Pgp, and that this induction appears to be stable despite a 3-week drug-free period.

Keywords: drug resistance; induction of MDR1 expression; anthracycline analogues; Pgp expression; drug accumulation

Drug resistance is a common problem in acute leukaemia (Mickenna et al, 1997). Patients often relapse with unresponsive disease after an initial response to treatment with cytotoxic drugs (Rothenberg et al, 1989). The expression of P-glycoprotein (Pgp) encoded by the MDR1 gene (Deuchars and Ling, 1989), is a well-known mechanism of multidrug resistance in relapsed acute leukaemia (Shustik et al, 1995; Bosch and Croop, 1996). The level of MDR1 gene expression in acute leukaemia is commonly increased after chemotherapy (Grogan et al, 1993; Nooter and Sonneveld, 1994). In addition, there appears to be a direct correlation between expression of the MDR1 gene de novo and outcome (survival) in this disease (Poeta et al, 1996).

Although the mechanisms underlying the effect of cytotoxic drugs on MDR1 gene expression and in turn the multidrug resistant (MDR) phenotype remain poorly understood, the acquisition of Pgp-mediated drug resistance during chemotherapy is usually thought to be due to the selection of drug-resistant cells (Chaudhary and Roninson, 1993; Gekeler et al, 1994; Manzano et al, 1996). Sikic and colleagues have clearly demonstrated this in a cell line model (Beketic-Oreskovic et al, 1994; Chen et al, 1994; Dumontet et al, 1996), under conditions in which up-regulation of Pgp was prevented. Although several attempts have been made to demonstrate that Pgp expression can be up-regulated, these studies have generally required long exposure times (72 h or more). Consequently, the selection of Pgp-expressing cells could not be ruled out from these studies (Manzano et al, 1996).

However, we have demonstrated that a rapid induction of the MDR1 gene can occur after the exposure of cells to anthracyclines in a human MDR cell line (CEM/A7R) known to express low-level MDR1 mRNA and P-glycoprotein (Hu et al, 1995). The induction of MDR1 was dose and time related and correlated with an increase in Pgp expression and drug resistance. The rapid increase in MDR1 gene expression after exposure to daunorubicin or epirubicin strongly supported the previous findings that the MDR1 gene promoter was activated by anti-cancer agents (Kohno et al, 1989). Similar effects have been reported in rodent cell lines (Chin et al, 1990; Fardel et al, 1997). This induction of MDR1 gene expression may have an important role in our understanding and treatment of drug-resistant tumours, as it can be prevented by cyclosporin A (CyA) and its analogue PSC 833 (Hu et al, 1996).

Alternative approaches designed to overcome the MDR phenotype include the use of new lipid-soluble compounds that are not substrates for Pgp (De Vries et al, 1990; Michieli et al, 1993). However, the effect of these agents on MDR1 gene expression is unknown. The present study was designed to investigate whether two new lipid-soluble anthracyclines, 4-demethoxydaunorubicin (idarubicin, IDA) and MX2, a new morpholino-anthracycline,
were able to up-regulate *MDR1* gene expression compared with the classic anthracycline epirubicin (EPI).

**MATERIALS AND METHODS**

**Materials**

EPI and IDA and verapamil were obtained commercially from Farmitalia (Melbourne, Australia). MX2 was a gift from Kirin Brewery Company (Japan). Verapamil was dissolved in 0.9% saline solution. PSC 833 was obtained from Sandoz Pharma (Basel, Switzerland) and initially dissolved in absolute alcohol before being diluted in RPMI-1640 to give a stock solution of 0.5 mg ml\(^{-1}\) (the final ethanol concentration was 35%). RPMI-1640 was purchased as a powder (Gibco) and supplemented with 10% fetal calf serum (FCS) (Trace Biosciences, Melbourne, Australia), gentamicin (80 μg ml\(^{-1}\)), minocycline (1 μg ml\(^{-1}\)), Hepes (20 mM), sodium bicarbonate (0.21%) and glutamine (0.8 mM). Monoclonal antibody (mAb) MRK 16 to Pgp was generously provided by Dr Takashi Tsuruo (Division of Experimental Chemotherapy, Japanese Foundation for Cancer Research). A fluorescein-labelled F(ab')\(_2\), fragment of sheep anti-mouse IgG was purchased from Silenus Laboratories (Melbourne, Australia). The cDNA probe pHDR5A was a gift from Dr M Gottesman and Dr Ira Pastan (Laboratory of Molecular Biology, National Institutes of Health, Bethesda, MD, USA). The cDNA glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was a gift from Dr Mark Ross (Ludwig Institute for Cancer Research, Melbourne, Australia). Propidium iodide was purchased from Sigma Chemical (St Louis, MO, USA).

**Cell lines and drug treatment**

The studies were carried out in a variant human T-cell leukaemia MDR cell line, CEM/A7R. This line was derived from a classic MDR cell line CEM/A7, selected for low-level doxorubicin (DOX) resistance by stepwise selection of the parental line, CCRF-CEM, cultured in increasing concentrations of DOX (Zaleberg et al., 1994). The resistant line CEM/A7 was maintained in conditioned medium containing 0.07 μg ml\(^{-1}\) of DOX. The variant line (now stable for over 3 years) was established by culturing the CEM/A7 cells in the absence of DOX before being subcloned and designated as the CEM/A7R line. This line was not exposed to DOX or other Pgp substrates except in the specific experiments described below. At the time of these experiments, all lines were mycoplasma-free based on the mycoplasma TC Rapid kit (Gen-Probe, San Diego, CA, USA).

**Table 1** Chemosensitivity of the CEM/A7R and parental CCRF-CEM cell lines to EPI, MX2, IDA and 5-FU

| Drug | IC\(_{10}\) (μg ml\(^{-1}\)) | IC\(_{50}\) (μg ml\(^{-1}\)) | IC\(_{90}\) (μg ml\(^{-1}\)) | IC\(_{10}\) (μg ml\(^{-1}\)) | IC\(_{50}\) (μg ml\(^{-1}\)) | IC\(_{90}\) (μg ml\(^{-1}\)) |
|------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|
| EPI  | 0.103 ± 0.002   | 0.373 ± 0.041 (5.4) | 0.965 ± 0.035 | 0.008 ± 0.001 | 0.075 ± 0.003 | 0.128 ± 0.022 |
| MX2  | 0.002 ± 0.002   | 0.455 ± 0.011 (3.2) | 0.107 ± 0.009 | 0.004 ± 0.001 | 0.014 ± 0.003 | 0.043 ± 0.003 |
| IDA  | 0.003 ± 0.001   | 0.022 ± 0.008 (3.1) | 0.080 ± 0.025 | 0.002 ± 0.001 | 0.007 ± 0.001 | 0.016 ± 0.002 |
| 5FU  | 0.180 ± 0.04    | 0.51 ± 0.22 (1.0) | 2.60 ± 0.230 | 0.20 ± 0.008 | 0.454 ± 0.122 | 2.615 ± 0.235 |

IC\(_{10}\), IC\(_{50}\) and IC\(_{90}\) were determined as described in the Materials and methods section. Results are expressed as the average concentration (μg ml\(^{-1}\)) ± standard deviation (calculated from three experiments). Each experiment was performed in triplicate. Figures in parentheses represent relative resistance (see ‘Materials and methods’).

The CEM/A7R cells in exponential growth phase were collected 2 days after subculture. The cells were washed, counted and resuspended in 20 ml of fresh medium to a total cell number of 5 × 10\(^{5}\)–1 × 10\(^{10}\). The cells were treated with various concentrations of EPI, IDA and MX2 for 4–24 h, then harvested and washed three times with cold phosphate-buffered saline (PBS) for the analysis of *MDR1* gene expression. Cell viability was determined (after staining by trypan blue) using phase-contrast microscopy to detect cells of abnormal size or granularity. Non-viable cells were excluded from flow cytometric analysis by propidium iodide staining.

**Growth assays**

The sensitivity of each of the cell lines to a variety of chemotherapeutic drugs was determined by a standard growth inhibition assay (Tsuruo et al., 1981). Briefly, after determining cell viability, 2 × 10\(^{5}\) of the tested cells were exposed to varying concentrations of each tested drug in the presence or absence of verapamil (Vp) or PSC 833 in 12-well plates. The cells were incubated at 37°C in a humidified chamber containing 5% carbon dioxide in air for 3 days and counted using an automated coulter counter (Hu et al., 1990a). Results are expressed as the increase in cell number of drug-exposed cells as a percentage of the increase in untreated control cells. The IC\(_{50}\), IC\(_{90}\) and IC\(_{90}\) for each drug were determined by calculating the drug concentration required to inhibit cell growth by 10%, 50% and 90%. Relative resistance represents the ratio of the IC\(_{90}\) of the resistant CEM/A7R cell line compared with the parental CCRF-CEM cell line.

**RNA extraction and Northern blot analysis**

RNA was isolated by the guanidinium thiocyanate method described by Chomczynski and Sacchi (1987). Twenty micrograms of total cellular RNA was size fractionated on a 1.5% agarose gel containing 2.2 M formaldehyde and transferred onto nylon filters (Hybond-N, Amersham, UK) for *MDR1* hybridization. The filters were probed with the plasmid pHDR5A containing a 1.4-kb *MDR1* cDNA (Ueda et al., 1987) and then reprobed with a 32P-labelled GAPDH cDNA for normalization. The pHDR5A probe predominantly recognizes the *MDR1* gene under the high stringency conditions used in this study. The filters were prehybridized overnight at 42°C in hybridization buffer containing 50% formamide, 5 × SSPE (1 × SSPE containing 0.15 M sodium chloride, 0.001 M sodium dihydrogen phosphate and 0.001 M EDTA), 5 × Denhardt’s solution.
0.5% sodium dodecyl sulphate (SDS) and 1% skimmed milk powder. Hybridization was carried out in the same buffer. The pHDR5A and GAPDH cDNAs were randomly primed with [α-32P]-dCTP. Labelled cDNA (10^6 c.p.m.) was added to each millilitre of hybridization buffer. The filters were washed sequentially in 2·SSPE with 0.1% SDS at 42°C for 15 min, 1·SSPE with 0.1% SDS at 65°C for 30 min and finally 0.1·SSPE with 0.1% SDS at room temperature for 15 min. The filters were then exposed to radiographic film at –70°C using intensifying screens, or radioactive signals were quantitated by scanning on a phosphorimager using Image Quant software (Molecular Dynamics, Melbourne, Australia).

**Pgp expression**

Flow cytometry was used to measure Pgp expression. Cells were collected and washed three times in medium containing 10% FCS. MRK16, a mAb to an external epitope of Pgp (final concentration 10 μg ml⁻¹), was added to cells at room temperature (RT) for 20 min. A non-specific murine mAb (IgG₂a, Becton Dickinson, Sydney, Australia) was used as the isotype control. After a further three washes, cell pellets were resuspended in the same volume of phosphate-buffered saline (PBS) containing 10 μl of a 1:10 dilution of a fluorescein-conjugated F(ab')₂ fragment of sheep anti-mouse IgG antibody (Silenus Laboratories) for 20 min at RT in the dark. Cells were washed once again (×3) and then analysed in a FACScan flow cytometer (Becton Dickinson). Mean fluorescence intensity was recorded for each tested population (after correcting for non-specific binding) to provide an estimate of relative MRK-16 binding.
Changes in [3H]daunomycin accumulation were used as a functional assay of Pgp (Hu et al., 1990b). Cells were washed three times with PBS and resuspended in fresh medium for 1 h at 37°C in a humidifier before performing drug accumulation studies. The cells were adjusted to a concentration of 5 x 10^6 ml^-1 and viability assessed with trypan blue. Cells were added to 96-well plates to give a final number of 5 x 10^5 cells per well and incubated at 37°C with tracer amounts of [3H]daunomycin (final concentration 1.85 x 10^-5 Bq ml^-1, 0.05 µg ml^-1). The cells were harvested onto glass-fibre filters at designated times with an automated cell harvester (Cambridge Technology). The filter papers were dried and dissolved in 5 ml of a liquid scintillation cocktail (Ultima Cold, Packard) before radioactivity was measured. All assays were performed in triplicate.

Statistics

Analysis of variance was used to compare intracellular levels of [3H]daunomycin after exposure of cells to various experimental conditions.

RESULTS

Cytotoxicity of IDA, MX2 and 5-FU

The relative cytotoxicity of the two lipid-soluble anthracyclines IDA and MX2 was compared with the classic anthracycline epirubicin (EPI), as well as the unrelated drug 5-FU – a drug not pumped by Pgp. The IC_{10}, IC_{50} and IC_{90} for each drug were determined in a 3-day growth inhibition assay (Table 1) in the drug-resistant CEM/A7R and the parental drug-sensitive line CCRF-CEM.

On a weight basis, IDA and MX2 were 17- and eightfold more active than EPI in the drug-resistant CEM/A7R and 11- and fivefold more active than EPI in the parental line CCRF-CEM, respectively, when comparing doses that inhibited cell growth by fivefold more active than EPI in the drug-resistant line CEM/A7R and 11- and 3-day growth inhibition assay (Table 1) in the drug-resistant CEM/A7R line over a 24-h exposure. Cells in exponential growth phase were treated with and without IDA at the IC_{10} (0.002 µg ml^{-1}), IC_{50} (0.02 µg ml^{-1}), and IC_{90} (0.08 µg ml^{-1}) levels or MX2 at IC_{10} (0.02 µg ml^{-1}) IC_{50} (0.05 µg ml^{-1}), IC_{90} (0.1 µg ml^{-1}) for 4 h. RNA was then extracted and subjected to Northern blot analysis and scanned on a phosphorimager as described in the Materials and methods section. Results are expressed as the ratio of MDR1 to GAPDH RNA after signals were normalized with respect to the CCRF-CEM signal. Columns, means of triplicate analyses of Northern blots; bars, s.d. These experiments were repeated on three separate occasions with similar findings. The data presented are representative of one such experiment.

![Graph](image)

Figure 3 Effect of IDA or MX2 on induction of MDR1 gene expression in the CEM/A7R cells after a 4-h exposure. CEM/A7R cells in exponential growth phase were treated with and without IDA at the IC_{10} (0.002 µg ml^{-1}), IC_{50} (0.02 µg ml^{-1}), and IC_{90} (0.08 µg ml^{-1}) levels or MX2 at IC_{10} (0.02 µg ml^{-1}) IC_{50} (0.05 µg ml^{-1}), IC_{90} (0.1 µg ml^{-1}) for 4 h. RNA was then extracted and subjected to Northern blot analysis and scanned on a phosphorimager as described in the Materials and methods section. Results are expressed as the ratio of MDR1 to GAPDH RNA after signals were normalized with respect to the CCRF-CEM signal. Columns, means of triplicate analyses of Northern blots; bars, s.d. These experiments were repeated on three separate occasions with similar findings. The data presented are representative of one such experiment.

![Graph](image)

Figure 4 The effects of 5-FU on the induction of the MDR1 gene in the CEM/A7R line over a 24-h exposure. Cells in exponential growth phase were treated with (or without) 5-FU at the IC_{10} (0.2 µg ml^{-1}), IC_{50} (0.5 µg ml^{-1}), IC_{90} (2 µg ml^{-1}) or IDA at the IC_{10} level (0.02 µg ml^{-1}) as a comparison. The 3P-labelled MDR1 and GAPDH bands were scanned on a phosphorimager using Image Quant Software (Molecular Dynamics) and the results are expressed as the ratio of MDR1 to GAPDH RNA after signals were normalized with respect to the CCRF-CEM signal. Columns, means of triplicate analyses of Northern blots; bars, s.d. Similar results were seen in repeated experiment.

Gene expression

The effects of EPI, IDA, MX2 or 5-FU on the induction of the MDR1 gene in the CEM/A7R line were compared at their respective IC_{10}, IC_{50} and IC_{90} concentrations over a 4- or 24-h period of drug exposure. All samples collected for the analysis of MDR1 gene expression were harvested immediately after drug treatment. The up-regulation of MDR1 gene expression by each drug was semiquantitatively assessed by scanning Northern blots on a phosphorimager.

We had previously demonstrated that 1.5 µg ml^{-1} of EPI (IC_{90} concentration) induced the expression of MDR1 mRNA as early as 4 h after such exposure. In the present study, the effect of EPI on the induction of the MDR1 gene was examined at the IC_{10} and IC_{90} concentrations over a short time period (4-6 h). Up-regulation of MDR1 mRNA was observed over 4-6 h with a two- to fivefold increase in MDR1 mRNA noted at 0.1 (IC_{10}) and 1.0 (IC_{90}) µg ml^{-1} of EPI respectively (Figure 2A and B).

The impact of IDA and MX2 on the induction of MDR1 gene expression was examined at equieffective concentrations over 4 h. Both drugs induced a similar increase in MDR1 mRNA levels in a dose-dependent manner (Figure 3). A two- to threefold increase in MDR1 mRNA was observed at the IC_{10} (0.002, 0.02 µg ml^{-1}) and IC_{90} (0.02, 0.05 µg ml^{-1}) concentrations of IDA and MX2, and a fivefold increase at the IC_{90} concentrations (0.08, 0.1 µg ml^{-1}) of
IDA and MX2 respectively (Figure 3). When the exposure time was prolonged up to 24 h, a fivefold increase of MDR1 mRNA was observed at the IC_{50} concentrations of IDA (0.02 μg ml^{-1}) or MX2 (0.05 μg ml^{-1}) (data not shown).

The potential induction of the MDR1 gene by 5-FU was examined at 0.2, 0.5 and 2.0 μg ml^{-1} (IC_{10}, IC_{50} and IC_{90}) levels respectively. Although no obvious increase in MDR1 expression was observed at any concentration of 5-FU after 4 h (data not shown), Northern analysis revealed induction had occurred in a dose-dependent manner after 24 h (Figure 4). A threefold induction in MDR1 expression was seen at the IC_{50} level (2 μg ml^{-1}) compared with the fivefold induction of MDR1 at the IC_{50} level (0.02 μg ml^{-1}) of IDA (Figure 4).

For each of the four drugs used in these experiments, treated cells were stained with trypan blue to assess cells for visible cell damage. Careful examination using phase-contrast microscopy for change in cell morphology and/or increased granularity revealed no visible evidence of cell damage within 4–24 h at any of the drug concentrations used.

**Pgp expression**

To determine whether the increased levels of MDR1 mRNA expression induced by IDA, MX2 and 5-FU were accompanied by corresponding changes in Pgp levels, antigen density (mean channel fluorescence or mcf) was measured by flow cytometry. The CEM/A7R cells were exposed for 24 h to approximately the IC_{90} levels of IDA, MX2 (0.1 μg ml^{-1}), 5-FU (2.0 μg ml^{-1}) or EPI (0.5 μg ml^{-1}) before being subjected to Pgp analysis (Figure 5). In parallel to the increase in the MDR1 mRNA levels (Figure 3), Pgp expression was increased five- to sevenfold with EPI, MX2 and IDA (mcf 36.65, 25.98 and 22.20 respectively) and threefold with 5-FU (mcf 18.74). In comparison, the mcf of untreated CEM/A7R cells was 4.2.

To examine whether the induction in MDR1 gene expression was stable, CEM/A7R cells were treated overnight with 0.1 μg ml^{-1} MX2 (IC_{90}) or 2.0 μg ml^{-1} 5-FU (IC_{90}). The drug-treated cells were then washed three times and allowed to grow in drug-free medium for either 72 h or 3 weeks before being subjected to a further analysis of MDR1 mRNA levels (data not shown) or Pgp expression. In the MX2- and IDA-treated CEM/A7R cells, Pgp expression remained two- to threefold higher (mcf 13.50 and 11.09) than the untreated CEM/A7R cells (mcf 4.66) 3 weeks after drug exposure. In contrast, the increased Pgp levels in cells treated with 5-FU returned to base line (mcf 4.69) within 72 h of stopping drug treatment (data not shown).

To assess the functional activity of Pgp, [3H]Daunomycin accumulation was determined in the CEM/A7R cells. After an overnight exposure to EPI (0.5 μg ml^{-1}), IDA (0.1 μg ml^{-1}), MX2

---

**Figure 5** Flow cytometric analysis of Pgp expression using MRK-16 binding (filled histogram) compared with an IgG2a control (unfilled histogram) in the CEM/A7R line with or without a 24-h exposure to IC_{90} concentrations of EPI (1.0 μg ml^{-1}), IDA, MX2 (0.1 μg ml^{-1}) or 5-FU (2.0 μg ml^{-1}) before measurement of Pgp levels as described in the Materials and methods section.
(0.1 μg ml⁻¹) or 5-FU (2.0 μg ml⁻¹), the cells were maintained in drug-free medium for 3 weeks before drug accumulation was quantified. Compared with the untreated CEM/A7R cells, the intracellular levels of [³H]daunomycin were significantly lower in the EPI-, IDA- and MX2-treated CEM/A7R cells, but were unchanged in the 5-FU-treated cells (Figure 6). Growth inhibition assays also showed a two- to threefold increase in resistance to EPI in MX2-, IDA- and EPI-treated cells after 3 weeks in drug-free medium. In contrast, the drug sensitivity of 5-FU-treated cells was the same as that of untreated CEM/A7R cells (Figure 7).

DISCUSSION

In this report, we investigated whether the two lipid-soluble anthracycline analogues IDA and MX2 could up-regulate MDR1 gene expression in a human MDR, T-cell leukaemia line, CEM/A7R, and its parental line, CCRF-CEM. Both drugs are thought to be poor substrates for Pgp-mediated transport (de Vries and Zijlstra, 1990; Ross et al, 1995). Initially, we compared the chemosensitivity (in the presence or absence of Vp or PSC 833) of each drug in the cell lines.

Verapamil (5 μM) and PSC 833 (1 μM) dramatically decreased the resistance of the CEM/A7R line to EPI, but had no effect on the sensitivity of this drug-resistant line to MX2 and only slightly increased the sensitivity to IDA (Figure 1). These findings are consistent with the observation that both anthracycline analogues are highly lipophilic and diffuse rapidly through the cell membrane to bind to DNA, thereby interfering with the capacity of cells expressing Pgp to pump these drugs (Horichi et al, 1990; Watanabe et al, 1991; Berman and McBride, 1992) and thus overcoming drug resistance. Although IDA and MX2 are less susceptible to this mechanism of resistance compared with the drug-sensitive line, detectable levels of resistance to IDA and MX2 were still observed in the resistant CEM/A7R cells (Table 1).

The effects of IDA, MX2 and 5-FU on the induction of MDR1 gene expression were investigated at equieffective concentrations with respect to the inhibition of cell growth in a 72-h cell growth inhibition assay. When MDR1 mRNA expression was analysed by Northern blotting, a two- to fivefold increase was observed in the CEM/A7R cells 4 h after treatment with IDA, MX2 or EPI at concentrations ranging from the IC₁₀ to IC₅₀ level. In contrast, 5-FU failed to up-regulate MDR1 expression after a 4-h exposure, although induction of MDR1 gene expression was seen after a 24-h exposure. The effects of these drugs on MDR1 gene expression was confirmed by flow analysis, demonstrating a concomitant increase in Pgp expression. Up-regulation of Pgp expression by IDA and MX2 was stable as demonstrated by the increase in Pgp levels, drug resistance and decrease in drug accumulation in the IDA- and MX2-treated CEM/A7R cells 3 weeks after the removal of these agents from the culture medium (Figures 5–7).

Other investigators have reported the up-regulation of MDR1 promoter activity in reporter gene assays by cytotoxic drugs (Kohno et al, 1989) as well as many other factors (Rohlf and Glazer, 1995). These findings have been controversial with respect to their relevance in the clinical context, as the endogenous promoter does not always behave in an analogous manner to the transfected promoter. For example, Tanimura et al (1992) and Ferrandis and Benard (1993) have demonstrated that a transfected promoter is active in drug-sensitive cells in which the endogenous promoter is not active.

Increased MDR1 mRNA and Pgp expression have also been reported in human cell lines after their exposure to cytotoxic drugs (Chaudhary and Roninson, 1993; Gekeler et al, 1994). However, the possibility that selection had occurred could not be excluded (reviewed in Manzano et al, 1996), as drug-induced MDR1 expression usually occurred after a 72-h exposure to sublethal concentrations of cytotoxins and was associated with the appearance of visible morphological cell damage.

The present study was designed to examine the role of the two anthracycline analogues IDA and MX2 on the up-regulation of MDR1 gene expression for a range of concentrations (IC₁₀, IC₅₀ and IC₉₀ levels) within 4 and 24 h. In our study, the increase in MDR1 expression was not related to the appearance of cytological damage and was seen at concentrations as low as the IC₁₀ level for each drug.

Up-regulation of MDR1 gene expression has mainly been observed for drugs which are substrates for Pgp, although one study demonstrated that a non-Pgp substrate, cytarabine, was able to induce MDR1 expression (after a 72-h exposure) which was stable after withdrawal of the drug for more than 6 weeks (Chaudhary and Roninson, 1993). In this report, we observed that 5-FU, also not a substrate for Pgp, could up-regulate MDR1 mRNA levels. However, this appeared to be a transient increase because the level of Pgp returned to baseline within 72 h of removal of the drug. These findings suggest that the mechanism by which 5-FU acts probably differs from that used by other anthracyclines which result in a sustained increase in Pgp expression.

It is likely that the cellular response to cytotoxic stress is to activate a number of defence mechanisms via stress response pathways (Osborn and Chambers, 1996). The up-regulation of Pgp expression may represent only one of the results of this response to these stress mechanisms. However, this finding would not be expected to confer resistance to IDA or other drugs that are not pumped by Pgp (Consul et al, 1996; Hargrave et al, 1995). Thus, the up-regulation of Pgp expression in response to such drugs does not necessarily confer a survival advantage. In fact, it is generally accepted that the treatment of relapsed refractory leukaemia with idarubicin/cytarabine is associated with higher rates of complete remission and longer survival compared with daunorubicin/cytarabine (Carella et al, 1993; Berman, 1993).

The mechanism by which these lipid-soluble anthracyclines, or indeed the classic Pgp substrate EPI, up-regulate Pgp expression is not known. The fact that induction can occur rapidly (in 4 h) strongly suggests that up-regulation involves transcription of the MDR1 gene, perhaps involving stress response pathways. Osborn and Chambers (1996) demonstrated that a c-jun NH₂-terminal protein kinase (JNK), a member of the mitogen-activated protein kinase family, is activated by a variety of stressful stimuli, including exposure to cytotoxic agents. In their system, exposure to doxorubicin resulted in increased JNK activity and increased MDR1 mRNA levels. Rohlf and Glazer (1995) suggested a number of signalling pathways may act on MDR1 gene expression. Which, if any, of these pathways are involved in the induction response observed in our line is the focus of further work in our laboratory.

ABBREVIATIONS

IDA, 4-demethoxydaunorubicin (Idarubicin); MX2, 3′-deamino-3′-morpholino-13-deoxo-10-hydroxycarminomycin; EPI, epirubicin; DOX, doxorubicin; 5-FU, 5-fluorouracil; CyA, cyclosporin A; Vp, verapamil; MDR, multidrug resistance; Pgp, P-glycoprotein; mcf, mean channel fluorescence.
ACKNOWLEDGEMENT

This study was supported in part by the Anti-Cancer Council of Victoria and Department of Veterans Affairs, Canberra, Australia.

REFERENCES

Beketic-Oreskovic L, Duran GE, Chen G, Dumontet C and Sikic BI (1995) Decreased mutation rate for cellular resistance to doxorubicin and suppression of mdr1 gene activation by the cyclosporin PSC 833. J Natl Cancer Inst 87: 1593–1602

Berman E (1993) A review of idarubicin in acute leukemia. Oncology 7: 91–104

Berman E and McBride M (1992) Comparative cellular pharmacology of daunorubicin and idarubicin in human multidrug-resistant leukemia cells. Blood 79 (1): 3267–3273

Bosch I and Croop J (1996) P-glycoprotein multidrug resistance and cancer. Biochim Biophys Acta 1288: F37–F54

Carella AM, Carlier P, Pungolino E, Resegotti L, Liso V, Stasi R, Montillo M, Iacopino P, Mirto S, Pagano L, Leoni F, Martelli FM, Raimondi FD, Porcellini A, de Rui L, Nosari AM, Damasio E, Miraglia E, Fiorioni G, Ricciuti F, Carotenuto M, Longinotti M, Defazio D, Fazi P and Mandelli F (1993) Idarubicin in combination with intermediate-dose cytarabine and VP-16 in the treatment of refractory or rapidly relapsed patients with acute myeloid leukemia. Leukemia 7: 196–199

Chaudhary PM and Roninson IB (1993) Induction of multidrug resistance in human cells by transient exposure to different chemotherapeutic drugs. J Natl Cancer Inst 85: 632–639

Chen G, Jaffrêzo JP, Fleming WH, Duran GE and Sikic BI (1994) Prevalence of multidrug resistance related to activation of the MDR1 gene in human sarcoma mutants derived by single-step doxorubicin selection. Cancer Res 54: 4980–4987

Chen KV, Chauhan SS, Pastan I and Gottesman MM (1990) Regulation of mdr RNA levels in response to cytotoxic drugs in rodent cells. Cell Growth Differ 1: 361–365

Chomczynski P and Sacchi N (1987) Single-step method of RNA isolation by acid guanidinium thiocyanate–phenol–chloroform extraction. Anal Biochem 162: 156–159

Consoli U, Priebke W, Ling YH, Mahadevia R, Griffin M, Zhao S, Soler RP and Andreeff M (1996) The novel anthracycline annamycin is not affected by P-glycoprotein related multidrug resistance: comparison with idarubicin and doxorubicin in HL60 leukemia cell lines. Blood 88: 633–644

de Vries EGE and Zijlstra JG (1990) Morpholinyl anthracyclines: option for reversal of anthracycline resistance. Eur J Cancer 26: 659–660

Deuschars KL and Ling V (1989) P-glycoprotein and multidrug resistance in cancer chemotherapy. Semin Oncol 16: 156–165

Dumontet C, Duran GE, Steger KA, Beketic-Oreskovic I and Sikic BI (1996) Resistance mechanisms in human sarcoma mutants derived by single-step exposure to paclitaxel (Taxol). Cancer Res 56: 1091–1097

Fardel O, Lecureur V, Daval S, Corlu A and Guillouzo A (1997) Up-regulation of P-glycoprotein expression in rat liver cells by acute doxorubicin treatment. Eur J Biochem 246: 186–192

Ferrandis E and Benard J (1993) Activation of the human MDR1 gene promoter in differentiated neuroblasts. Int J Cancer 54: 987–991

Gekeler V, Beck J, Noller A, Wilisch A, Frese G, Neumann M, Handre贯通tinger R, Ehninger G, Probst H, Neithammer D (1994) Drug-induced changes in the expression of MDR-associated gene: investigations on cultured cell lines and chemotherapeutically treated leukemias. Ann Hematol 69: 519–523

Grogan TM, Spier CM, Salmon SE, Matzner M, Rybksi J, Weinstein RS, Schaper RJ and Dalton WS (1993) P-glycoprotein expression in human plasma cell myeloma: correlation with prior chemotherapy. Blood 81: 490–495

Hargave RM, Davey MW, Davey RA, Kidman AD (1995) Development of drug resistance is reduced with idarubicin relative to other anthracyclines. Anti-Cancer Drugs 6: 432–437

Horiguchi N, Tagiri H, Sugimoto Y, Bungo M, Nishiyama M, Fourcade A, Lampidis TJ, Kasahara K, Sasaki Y, Takahashi T and Saijo N (1990). 3′-Deamino-3′-morpholino-13-deoxy-10-hydroxycarmomicyn octaguanosine multidrug resistance by rapid influx following higher frequency of DNA single- and double-strand breaks. Cancer Res 50: 4698–4701

Hu XF, de Luise M, Martin TJ and Zalcberg JR (1990b) Effect of cyclosporin and verapamil on the cellular kinetics of doxorubicin. Eur J Cancer 26: 814–817

Hu XF, Martin TJ, Bell DR, de Luise M and Zalcberg JR (1990a) Combined use of cyclosporin A and verapamil in modulating multidrug resistance in human leukemia cell lines. Cancer Res 50: 2953–2957

Hu XF, Slater S, Wall DM, Kantharidis P,arkin JD, Cowan A and Zalcberg JR (1995) Rapid upregulation of mdr1 expression by anthracyclines in a classical multidrug-resistant cell line. Br J Cancer 71: 931–936

Hu XF, Slater S, Wall DM, Parkin JD, Kantharidis P and Zalcberg JR (1996) Cyclosporin A and PSC 833 prevent up-regulation of MDR1 expression by anthracyclines in a human multidrug-resistant cell line. Clin Cancer Res 2: 713–720

Kohno K, Sato S, Takano H, Matsuo K-I and Kuwano M (1989) The direct activation of human multidrug resistance gene (MDR1) by anticancer agents. Biochem Biophys Res Commun 165: 1415–1421

Manzano RG, Wright VK and Twentymann PR (1996) Rapid recovery of a functional MDR phenotype caused by MBP after a transient exposure to MDR drugs in a revertant human lung cancer cell line. Eur J Cancer 32A: 2136–2141

Michei S, Michelutti A, Damiani D, Pipan C, Paspadori D, Lauria F and Baccarani M (1993) A comparative analysis of the sensitivity of multidrug resistant (MDR) and non-MDR cells to different anthracycline derivatives. Leukemia & Lymphoma 9: 255–264

Mickens AL and Padua RA (1997) Revival of multidrug resistance in leukemia. Br J Haematol 96: 659–674

Nielson C, Maare C and Skovsegaard T (1996) Cellular resistance to anthracyclines. Gen Pharmacol 27: 251–255

Nooter K and Sonneveld P (1994) Clinical relevance of P-glycoprotein expression in hematological malignancies. Leukemia 18: 233–243

Osborn MT and Chambers TC (1996) Role of the stress-activated c-jun NH2-terminal protein kinase pathway in cellular response to adriamycin and other chemotherapeutic drugs. J Biol Chem 271: 30950–30955

Poeta GD, Stasi R,aronica G, Venditti A, Cox MC, Bruno A, Bucisano F, Masì M, Tribalto M, Amadori S and Papat G (1996) Clinical relevance of P-glycoprotein expression in novo acute myeloid leukemia. Blood 87: 1997–2004

Rohlff C and Glazer RI (1995) Regulation of multidrug resistance through the c-AMP and EGF signalling pathways. Cell Signalling 7: 431–443

Ross DD, Doyle LA, Yang W, Tong Y and Cornblatt B (1995) Susceptibility of idarubicin, daunorubicin and their C-13 alcohol metabolites to transport-mediated multidrug resistance. Biochem Pharmacol 50: 1673–1683

Rothenberg M, Mickley LA, Cole DE, Balis FM, Tsuruo T, Poplack D and Fojo AT (1988) Expression of the mdr1P gene in human sarcoma cells with and without multidrug resistance. Cancer Res 48: 2136–2141

Shustik C, Dalton W and Gros P (1995) P-glycoprotein-mediated multidrug resistance in tumor cells: biochemistry, clinical relevance and modulations. In Molecular Aspects of Medicine, pp. 1–78. Elsevier Science: London

Tanimura H, Kohno K, Sato S-I, Uchumi T, Miyazaki T, Kobayashi M and Kuwano M (1992) The human multidrug resistance 1 promoter has an element that responds to serum starvation. Biochem Biophys Comm 183: 917–924

Tsuruo T, Iida H, Tsukagoshi S and Sakurai Y (1981) Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res 41: 1967–1972

Ueda K, Clark DP, Chen C-J, Roninson IB, Gottesman MM and Pastan I (1987) The human multidrug resistance (mdr1) gene: cDNA cloning and transcription initiation. J Biol Chem 262: 5015–5020

Watanabe M, Konomi S, Naito M, Iose T, Takeda and Tsuruo T (1991) Cellular pharmacology of MX2, a new morpholino anthracycline, in human plectrotypic drug-resistant cells. Cancer Res 51: 151–157

Zalcberg JR, Hu XF, Wall DM, Murski S, Cole S, Nadalin G, De Luise M, Parkin JD, Vrazas V, Campbell L, and Kantharidis P (1994) Cellular and karyotypic characterization of two doxorubicin resistant cell lines isolated from the same parental human leukemia cell line. Int J Cancer 57: 522–528